Staging and treating lymphoma: PET-CT, the Lugano stages and treatment principles
- Treatment and support
Lymphoma treatment depends on three things: which lymphoma, how far it has spread and how fit the patient is. PET-CT answers the second.
What it is
Staging maps where the lymphoma is. PET-CT, which shows sugar-hungry tissue, is the standard for most lymphomas that take up the tracer, including Hodgkin, DLBCL and follicular lymphoma. The Lugano classification groups stages I–II as limited disease and III–IV as advanced; bulk (a very large mass) and B symptoms add risk. Treatment is then chosen by lymphoma type, stage, prognostic scores and fitness, and response is checked by repeat PET using the five-point Deauville scale.
What to know
- Stage I: one node region (or one extranodal site, IE); II: two or more regions on the same side of the diaphragm; III: nodes on both sides, or above the diaphragm plus the spleen; IV: spread to organs such as marrow, liver or lung.
- B symptoms: unexplained fever above 38 °C, drenching night sweats, loss of more than 10% of body weight in six months; in Lugano they are recorded for Hodgkin lymphoma.
- Bulky disease: a mass of about 10 cm or more, or a mediastinal mass wider than a third of the chest, which changes treatment in early-stage disease.
- PET-CT has largely replaced routine bone marrow biopsy for staging Hodgkin lymphoma and DLBCL.
- Deauville scores 1–3 at the end of treatment usually mean complete metabolic response; 4–5 mean residual active disease, which may need biopsy.
- Prognostic scores: IPI for DLBCL (age, LDH, performance status, stage, extranodal sites); FLIPI for follicular lymphoma.
How it is done (and why)
- Confirm the exact type on an excision or core biopsy; treatment differs completely between types.
- Stage with PET-CT, and add bone marrow biopsy only when PET cannot answer the question.
- Score the risk: stage, bulk, B symptoms, LDH, IPI or FLIPI, and the patient's fitness and heart, lung and kidney function.
- Prepare: hepatitis B, C and HIV tests, echocardiogram before anthracyclines, lung function before bleomycin, fertility preservation, vaccines.
- Treat by principle and type: Hodgkin, DLBCL and indolent lymphoma each follow their own plan (see the table below).
- Interim PET in Hodgkin lymphoma guides whether to intensify or reduce treatment.
- End-of-treatment PET defines response; relapsed aggressive lymphoma may go to salvage chemotherapy and autologous transplant, CAR-T or bispecifics.
Treatment principles by type
| Lymphoma | Limited stage (I–II) | Advanced stage (III–IV) | Key toxicity to watch |
|---|---|---|---|
| Hodgkin | Short combination chemotherapy, often with involved-site radiotherapy | Longer ABVD-type or brentuximab-containing combination chemotherapy, adjusted by interim PET | Bleomycin lung injury, late heart and breast effects after mediastinal radiotherapy |
| DLBCL | Anti-CD20 plus chemotherapy, fewer cycles, sometimes radiotherapy | Anti-CD20 plus anthracycline-based chemotherapy; CNS prophylaxis if high CNS risk | Anthracycline heart damage, neuropathy, hepatitis B reactivation |
| Follicular | Radiotherapy can be curative | Watch if low burden; anti-CD20 based when symptomatic or bulky | Infections from long B-cell depletion |
| Gastric MALT | H. pylori eradication, then radiotherapy if needed | Anti-CD20 based therapy | Monitor for regression by endoscopy |
Risks and precautions
- Hepatitis B reactivation during anti-CD20 therapy can cause fatal liver failure; carriers and those with past infection receive antiviral prophylaxis.
- Bleomycin lung toxicity presents as cough and breathlessness; patients who have received it are given only the oxygen they need in later anaesthesia.
- Young women treated with mediastinal radiotherapy for Hodgkin lymphoma have a higher lifetime risk of breast cancer and need earlier screening.
- Patients with Hodgkin lymphoma need irradiated cellular blood components, to prevent transfusion-associated graft-versus-host disease.
- Fertility preservation is offered before treatment, because alkylating agents and pelvic radiotherapy can cause infertility.
Monitoring and next step
- Baseline: full count, LDH, liver and kidney tests, uric acid, hepatitis B surface antigen and core antibody, hepatitis C, HIV.
- Before anthracyclines: echocardiogram; before bleomycin: lung function tests.
- Interim PET in Hodgkin lymphoma, and end-of-treatment PET for all FDG-avid lymphomas, read with the Deauville scale.
- Deauville 4–5 at the end of treatment, or a new lesion: biopsy before labelling it relapse.
Common traps
- Placing the spleen in the wrong stage: in Lugano spleen involvement with nodes above the diaphragm is stage III, not IV.
- Calling every PET-positive residual mass relapse: inflammation and healing can take up tracer; biopsy Deauville 4–5 before changing treatment.
- Starting anti-CD20 therapy without hepatitis B core antibody testing: the test comes before treatment.
- Ordering a routine marrow biopsy in Hodgkin lymphoma: PET-CT already shows the marrow.
- Treating asymptomatic low-burden follicular lymphoma at once: it adds toxicity without improving survival.
Test yourself
Think of the answer, then tap the question to see it.
A patient has nodes in the neck and the mediastinum only. Which Lugano stage is this, and why?
Stage II: two or more node regions, all on the same side (above) the diaphragm.
Why has PET-CT replaced routine bone marrow biopsy for staging Hodgkin lymphoma?
PET-CT detects marrow involvement reliably as focal uptake, and a biopsy adds little when PET is clear or already shows it.
An end-of-treatment PET shows a Deauville score of 5 in one node. What is the next step?
Biopsy the active site before calling it relapse, because inflammation can also take up the tracer; confirmed disease then leads to salvage treatment.
Which blood test must precede rituximab, and why?
Hepatitis B surface antigen and core antibody, because anti-CD20 therapy can reactivate hepatitis B and cause fatal hepatitis unless antiviral prophylaxis is given.
Elsewhere in DurgiPedia
- Nuclear medicine and PET: how they work
- Hodgkin lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Cancer immunotherapy: checkpoint inhibitors, CAR-T and vaccines
- Leukaemia, lymphoma and stem-cell transplant: nursing care and graft-versus-host warning signs
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Nuclear Medicine PET/CT Lymphomas Assessment, Protocols, and Interpretation (StatPearls (NCBI Bookshelf), 2026); Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Hodgkin Lymphoma Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); PET scan: MedlinePlus Medical Encyclopedia (MedlinePlus, U.S. National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
